Interview: Medtech’s Unique Market-Access Routes Demand Tailored Response For EU-Wide HTA
The European Commission is looking at initiatives for employing health technology assessment at the EU level. But the medtech industry is concerned that its own specific market-access routes are being overlooked while the commission focuses too narrowly on solutions more suited to the pharma industry. MedTech Europe’s Yves Verboven explains the industry's case in an interview.
You may also be interested in...
February sees some vitally important issues on the European Commission’s agenda, including areas where the medtech sector has been clamoring for progress in terms of clarity over the Commission's thinking and guidance documents. This year's meetings are plentiful and critical.
While the EU has selected the CND system as the basis for its nomenclature, GMDN is becoming increasingly valued on the US and international scene. How does it see its latest role panning out globally?
Updated medtech notified body figures from the European Commission always make headline news. But industry needs to see real appointments now, not a list of tricky-to-understand numbers.